109.00 -0.51 (-0.47%)
After hours: 5:29PM EDT
|Bid||107.25 x 800|
|Ask||109.00 x 800|
|Day's Range||108.88 - 112.56|
|52 Week Range||103.66 - 132.13|
|Beta (3Y Monthly)||0.27|
|PE Ratio (TTM)||13.82|
|Earnings Date||Oct 23, 2019|
|Forward Dividend & Yield||2.58 (2.31%)|
|1y Target Est||123.83|
INDIANAPOLIS , Aug. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD7, the third pivotal ...
INDIANAPOLIS, Aug. 22, 2019 /PRNewswire/ -- A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company (LLY) in a claim filed by Adocia S.A. over the companies' prior collaboration on a rapid-acting insulin. The panel of three arbitrators ruled that Lilly acted appropriately regarding Adocia's intellectual property, and while they denied Lilly's smaller counterclaim, ruled that Lilly is not liable for damages. "We're pleased with the panel's decision," said Michael J. Harrington, Lilly's senior vice president and general counsel.
AstraZeneca's (AZN) roxadustat gets a second marketing approval in China for treating anaemia caused by chronic kidney disease in non-dialysis-dependent patients.
NuCana (NCNA) suspends patient enrollment in the phase III study on Acelarin, currently evaluated for treating patients with metastatic pancreatic cancer, who were unfit for combination chemotherapy.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.
Elanco Animal Health agreed to buy Bayer's veterinary drugs unit on Tuesday in a cash and stock deal valued at $7.6 billion, creating the second largest maker of medicines for pets and livestock and expanding Elanco's reach online. The deal is the latest in the fast-growing animal health market, which has recently seen Elanco floated by Eli Lilly and Co and rival U.S. drugmaker Pfizer also spinning off its veterinary medicine business.
INDIANAPOLIS , Aug. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, September 9, 2019 to discuss data presented for its RET-Inhibitor, LOXO-292, at the 20 th ...
Shares of AbbVie leapt higher Friday after the Food and Drug Administration approved its new rheumatoid arthritis treatment — a potential rival to drugs from Eli Lilly and Pfizer.
Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry.
Lilly's (LLY) Taltz is an important revenue driver for Lilly. Top-line data from a study shows that Taltz helps more plaque psoriasis patients achieve 100% skin clearance compared to Tremfya.
INDIANAPOLIS , Aug. 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is launching an open innovation challenge to encourage individuals and teams across the U.S. to identify and submit pioneering ...
Lilly said Tuesday ahead of the market open that Talz, a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine, met the primary and all major secondary endpoints up to 12 weeks in the Phase 4 IXORA-R study. Taltz has been approved for treating adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and also for adults with psoriatic arthritis.
INDIANAPOLIS, Aug. 13, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO). The IXORA-R trial is the first completed head-to-head (H2H) trial between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as the primary endpoint.